What are the efficacy, indications, and contraindications of etoricoxib 60 mg compared with polmacoxib 2 mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Etoricoxib 60 mg vs Polmacoxib 2 mg: Effectiveness, Indications, and Contraindications

For osteoarthritis and acute pain management, etoricoxib 60 mg has substantially more robust clinical evidence demonstrating efficacy, but polmacoxib 2 mg represents a promising alternative with a potentially superior safety profile, particularly regarding gastrointestinal and cardiovascular risks.

Effectiveness Comparison

Etoricoxib 60 mg

Etoricoxib demonstrates well-established efficacy across multiple pain conditions. In osteoarthritis, it provides significant pain relief with a 30.7% improvement in WOMAC pain scores by day 14, along with 32.6% improvement in mechanical hyperalgesia 1. The 60 mg dose shows maximal efficacy in knee OA, with sustained effects over 14 weeks 2. For chronic low back pain, etoricoxib 60 mg produces significant reductions in pain intensity (-15.15 mm on VAS) maintained over 3 months, with corresponding improvements in disability scores (RMDQ -2.82) 3.

The evidence for etoricoxib is extensive, including multiple large randomized controlled trials demonstrating superiority over placebo and equivalence to traditional NSAIDs like diclofenac and naproxen 4, 2.

Polmacoxib 2 mg

Polmacoxib is a newer dual COX-2 and carbonic anhydrase inhibitor with more limited but emerging evidence. A 2024 randomized trial demonstrated non-inferiority to celecoxib 200 mg in Indian patients with knee/hip OA over 6 weeks 5. The dual mechanism theoretically minimizes gastrointestinal and cardiovascular adverse effects compared to traditional COX-2 inhibitors 6.

However, the evidence base for polmacoxib remains substantially smaller, with fewer long-term studies and limited data outside Asian populations 6.

Indications

Etoricoxib 60 mg

Approved indications include:

  • Osteoarthritis of knee and hip 7, 2
  • Rheumatoid arthritis 4
  • Acute gouty arthritis (unique among COX-2 inhibitors) 7, 4
  • Chronic low back pain 3
  • Ankylosing spondylitis 7

Polmacoxib 2 mg

Current evidence supports use in:

  • Mild to moderate osteoarthritis of knee and hip 5
  • Acute painful conditions (dental, postoperative pain) 6

The narrower indication profile reflects polmacoxib's newer status rather than proven inefficacy in other conditions.

Contraindications

Etoricoxib 60 mg

Absolute contraindications 8:

  • Known hypersensitivity to etoricoxib or sulfonamides
  • Active peptic ulcer or gastrointestinal bleeding
  • Inflammatory bowel disease
  • Severe heart failure (NYHA II-IV)
  • Established ischemic heart disease or stroke 7
  • Peripheral arterial disease
  • Uncontrolled hypertension (European Medicines Agency contraindication) 7
  • Perioperative pain in CABG surgery 8
  • Severe hepatic dysfunction
  • Severe renal impairment (creatinine clearance <30 mL/min)
  • Pregnancy and breastfeeding

Relative contraindications/cautions 9:

  • Cardiovascular risk factors (use with extreme caution)
  • History of hypertension (monitor closely; etoricoxib increases blood pressure more than other NSAIDs) 10
  • Elderly patients (increased GI and CV risk)
  • Concurrent anticoagulation or antiplatelet therapy

Polmacoxib 2 mg

Based on available data 11, 6:

  • Hypersensitivity to polymyxins or drug components
  • Standard NSAID contraindications likely apply (active GI bleeding, severe renal/hepatic impairment, pregnancy)

The contraindication profile for polmacoxib is less comprehensively defined due to limited post-marketing experience.

Critical Safety Considerations

Cardiovascular Risk

Etoricoxib carries significant cardiovascular concerns. The MEDAL program showed non-inferiority to diclofenac for thrombotic events (HR 1.02,95% CI 0.87-1.18), but this comparison is problematic because diclofenac itself increases cardiovascular risk 10. Etoricoxib and diclofenac are both highly COX-2 selective, placing them at the higher-risk end of the NSAID spectrum 10, 12.

In patients with cardiovascular disease or risk factors, etoricoxib should be avoided entirely 9. The 2008 NICE guidelines specifically recommend COX-2 inhibitors "other than etoricoxib 60 mg" as first choice when NSAIDs are needed 13.

Polmacoxib's dual mechanism theoretically reduces cardiovascular risk compared to pure COX-2 inhibitors, but long-term cardiovascular outcome data are lacking 6.

Gastrointestinal Risk

Etoricoxib reduces GI discontinuations by 50% versus diclofenac and demonstrates fewer upper GI perforations, ulcers, or bleeds compared to non-selective NSAIDs 7, 4. However, when combined with aspirin, the GI protective advantage disappears 14.

For patients requiring gastroprotection: Co-prescribe proton pump inhibitors with either agent 15, 9.

Hypertension

Etoricoxib increases blood pressure more than other NSAIDs, with higher discontinuation rates due to hypertension-related adverse effects versus diclofenac 10, 7. Monitor blood pressure within 2 weeks of initiation and regularly thereafter.

Practical Algorithm for Selection

Step 1: Assess cardiovascular risk

  • If established CVD, stroke, or multiple CV risk factors → Avoid etoricoxib entirely; consider polmacoxib with caution or use paracetamol/topical NSAIDs 13, 9
  • If low CV risk → Proceed to Step 2

Step 2: Assess blood pressure

  • If uncontrolled hypertension → Etoricoxib contraindicated 7; consider polmacoxib or alternative
  • If controlled/normal BP → Proceed to Step 3

Step 3: Assess GI risk

  • If high GI risk (age >65, prior ulcer, concurrent anticoagulation) → Either agent acceptable with mandatory PPI co-prescription 9
  • If low GI risk → Proceed to Step 4

Step 4: Consider evidence base and indication

  • For established indications with robust evidence (OA, RA, gout, chronic LBP) → Etoricoxib 60 mg preferred due to extensive efficacy data [7-3,1]
  • For mild-moderate OA in patients prioritizing safety over extensive evidence → Polmacoxib 2 mg reasonable alternative 5, 6

Step 5: Dosing principles

  • Use lowest effective dose for shortest duration 13, 9, 12
  • Reassess need for continued therapy every 2-4 weeks
  • Consider intermittent rather than continuous use 12

Common Pitfalls

  1. Assuming etoricoxib is safe because it's COX-2 selective: Its high COX-2 selectivity actually increases cardiovascular risk 10, 12

  2. Using etoricoxib in patients on low-dose aspirin: The GI benefit is negated, and CV risk compounds 14

  3. Failing to monitor blood pressure: Etoricoxib uniquely increases BP; check within 2 weeks 10, 7

  4. Overlooking the NICE guideline caveat: NICE specifically excludes etoricoxib 60 mg from first-line COX-2 inhibitor recommendations 13

  5. Assuming polmacoxib is proven safer long-term: While mechanistically promising, long-term safety data remain limited 6

References

Research

Etoricoxib.

Drugs, 2002

Research

Clinical pharmacology of etoricoxib.

Expert opinion on drug metabolism & toxicology, 2005

Related Questions

How should etoricoxib be dosed, monitored, and what are its contraindications for adults with osteoarthritis or rheumatoid arthritis?
Is it safe to give etoricoxib (selective COX‑2 inhibitor) to a patient with supraventricular tachycardia who requires analgesia?
When is celecoxib preferred over ibuprofen, and what are the dosing recommendations, contraindications, and safety considerations for each NSAID?
What COX‑2 inhibitors (e.g., celecoxib, etoricoxib) can be used in a patient without active gastrointestinal ulcer disease, significant cardiovascular disease, severe renal impairment, or aspirin‑sensitive asthma?
Can I prescribe etoricoxib 90 mg once daily and pregabalin 75 mg twice daily for a patient with lumbar radiculopathy presenting with numbness and pain?
Why is enoxaparin (low‑molecular‑weight heparin) prescribed during pregnancy?
How should the laboratory abnormalities—marked leukocytosis with neutrophilia and monocytosis, left shift, severe hyponatremia, hyperglycemia, metabolic acidosis, acute kidney injury, hypoalbuminemia, and elevated alkaline phosphatase—be interpreted and managed?
Why did the patient develop seizures the day after receiving overnight sedation?
What investigations are required for a patient in India presenting with acute watery diarrhoea and moderate to severe dehydration?
What are the indications for oral vitamin D 50,000 IU therapy?
What occurs after termination of non‑sustained ventricular tachycardia, specifically the fusion beat and compensatory pause?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.